{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T04:59:35Z","timestamp":1774414775698,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Sirolimus is recently reported to have antitumour effects on a large variety of cancers. The present study was performed to investigate sirolimus's ability to inhibit growth in T24 bladder cancer cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>T24 bladder cancer cells were treated with various concentrations of sirolimus. MTT assay was used to evaluate the proliferation inhibitory effect on T24 cell line. The viability of T24 cell line was determined by Trypan blue exclusion analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Sirolimus inhibits the growth of bladder carcinoma cells and decreases their viability. Significant correlations were found between cell proliferation and sirolimus concentration (r = 0.830; p &lt; 0.01) as well as between cell viability and sirolimus concentration (r = -0.896; p &lt; 0.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Sirolimus has an anti-proliferation effect on the T24 bladder carcinoma cell line. The information from our results is useful for a better understanding sirolimus's anti-proliferative activity in the T24 bladder cancer cell line.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-9966-28-3","type":"journal-article","created":{"date-parts":[[2009,1,8]],"date-time":"2009-01-08T07:13:26Z","timestamp":1231398806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effect of sirolimus on urinary bladder cancer T24 cell line"],"prefix":"10.1186","volume":"28","author":[{"given":"Rosario","family":"Pinto-Leite","sequence":"first","affiliation":[]},{"given":"Pedro","family":"Botelho","sequence":"additional","affiliation":[]},{"given":"Eufemia","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Paula A","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Lucios","family":"Santos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2009,1,7]]},"reference":[{"key":"90_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics 2007. CA Cancer J Clin. 2007, 57: 43-66.","journal-title":"CA Cancer J Clin"},{"key":"90_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108.","journal-title":"CA Cancer J Clin"},{"key":"90_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/labinvest.2008.48","volume":"88","author":"J Crawford","year":"2008","unstructured":"Crawford J: The origins of bladder cancer. Lab Invest. 2008, 88: 686-693. 10.1038\/labinvest.2008.48.","journal-title":"Lab Invest"},{"key":"90_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/ncpuro0784","volume":"4","author":"G Dalbagni","year":"2007","unstructured":"Dalbagni G: The Management of Superficial Bladder Cancer. Nat Clin Pract Urol. 2007, 4: 254-260. 10.1038\/ncpuro0784.","journal-title":"Nat Clin Pract Urol"},{"key":"90_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ncponc1159","volume":"5","author":"T Choueiri","year":"2008","unstructured":"Choueiri T, Raghavan D: Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy persisting uncertainties. Nat Clin Pract Oncol. 2008, 5: 444-454. 10.1038\/ncponc1159.","journal-title":"Nat Clin Pract Oncol"},{"key":"90_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.urology.2006.10.041","volume":"69","author":"CN Sternberg","year":"2007","unstructured":"Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, Maase von der H, Tsukamoto T, Soloway MS: Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007, 69: 62-79. 10.1016\/j.urology.2006.10.041.","journal-title":"Urology"},{"key":"90_CR7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1634\/theoncologist.12-8-1007","volume":"12","author":"X Wan","year":"2007","unstructured":"Wan X, Helman LJ: The biology behind mTOR inhibition in sarcoma. Oncologist. 2007, 12: 1007-1018. 10.1634\/theoncologist.12-8-1007.","journal-title":"Oncologist"},{"key":"90_CR8","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1371\/journal.pmed.0050008","volume":"5","author":"TF Cloughesy","year":"2008","unstructured":"Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL: Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. PLoS Med. 2008, 5: e21-10.1371\/journal.pmed.0050008.","journal-title":"PLoS Med"},{"key":"90_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/ijc.11049","volume":"105","author":"L Santos","year":"2003","unstructured":"Santos L, Amaro T, Costa C, Pereira S, Bento MJ, Lopes P, Oliveira J, Criado B, Lopes C: Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer. 2003, 105: 267-272. 10.1002\/ijc.11049.","journal-title":"Int J Cancer"},{"key":"90_CR10","volume-title":"Eur Urol","author":"G Pignot","year":"2008","unstructured":"Pignot G, Bieche I, Vacher S, G\u00fcet C, Vieillefond A, Debr\u00e9 B, Lidereau R, Amsellem-Ouazana D: Large-scale Real-time Reverse Transcription-PCR Approach of Angiogenic Pathways in Human Transitional Cell Carcinoma of the Bladder: Identification of VEGFA as a Major Independent Prognostic Marker. Eur Urol. 2008, doi:10.1016\/j.eururo.2008.05.027"},{"key":"90_CR11","first-page":"295","volume":"3","author":"S Huang","year":"2002","unstructured":"Huang S, Houghtoun PJ: Inhibitors of mammalian target of rapamycin as a novel agents: from bench to clinic. Curr Opinion Invest Drugs. 2002, 3: 295-304.","journal-title":"Curr Opinion Invest Drugs"},{"key":"90_CR12","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.1158\/1078-0432.CCR-050008","volume":"10","author":"JP Dutcher","year":"2004","unstructured":"Dutcher JP: Mammalian target of rapamycin inhibition. Clin Cancer Res. 2004, 10: 6382-6387. 10.1158\/1078-0432.CCR-050008.","journal-title":"Clin Cancer Res"},{"key":"90_CR13","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","volume":"27","author":"M Hidalgo","year":"2000","unstructured":"Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000, 27: 6680-6686. 10.1038\/sj.onc.1204091.","journal-title":"Oncogene"},{"key":"90_CR14","first-page":"1758","volume":"7","author":"L Dudkin","year":"2001","unstructured":"Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA, Houghton PJ: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res. 2001, 7: 1758-1764.","journal-title":"Clin Cancer Res"},{"key":"90_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1677\/erc.0.0080249","volume":"8","author":"K Yu","year":"2001","unstructured":"Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, Gibbons JJ: mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001, 8: 249-258. 10.1677\/erc.0.0080249.","journal-title":"Endocr Relat Cancer"},{"key":"90_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","volume":"24","author":"DC Fingar","year":"2004","unstructured":"Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004, 24: 200-216. 10.1128\/MCB.24.1.200-216.2004.","journal-title":"Mol Cell Biol"},{"key":"90_CR17","first-page":"169","volume":"279","author":"AC Gingras","year":"2004","unstructured":"Gingras AC, Raught B, Sonenberg N: mTOR signaling to translation. Curr Top Microbiol Immunol. 2004, 279: 169-197.","journal-title":"Curr Top Microbiol Immunol"},{"key":"90_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrc1974","volume":"6","author":"DM Sabatini","year":"2006","unstructured":"Sabatini DM: mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006, 6: 729-734. 10.1038\/nrc1974.","journal-title":"Nat Rev Cancer"},{"key":"90_CR19","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","volume":"7","author":"JA Garcia","year":"2008","unstructured":"Garcia JA, Danielpour D: Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther. 2008, 7: 1347-1354. 10.1158\/1535-7163.MCT-07-2408.","journal-title":"Mol Cancer Ther"},{"key":"90_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ijc.2910110327","volume":"11","author":"J Buben\u00edk","year":"1973","unstructured":"Buben\u00edk J, Baresov\u00e1 M, Viklick\u00fd V, Jakoubkov\u00e1 J, Sainerov\u00e1 H, Donner J: Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer. 1973, 11: 765-773. 10.1002\/ijc.2910110327.","journal-title":"Int J Cancer"},{"key":"90_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.trim.2006.12.003","volume":"17","author":"JF Zhang","year":"2007","unstructured":"Zhang JF, Liu JJ, Lu MQ, Cai CJ, Yang Y, Li H, Xu C, Chen GH: Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transpl Immunol. 2007, 17: 162-168. 10.1016\/j.trim.2006.12.003.","journal-title":"Transpl Immunol"},{"key":"90_CR22","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/ijc.22442","volume":"120","author":"SA Lang","year":"2007","unstructured":"Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK, Stoeltzing O: Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer. 2007, 120: 1803-1810. 10.1002\/ijc.22442.","journal-title":"Int J Cancer"},{"key":"90_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.radonc.2006.11.004","volume":"82","author":"SA Weppler","year":"2007","unstructured":"Weppler SA, Krause M, Zyromska A, Lambin P, Baumann M, Wounters BG: Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol. 2007, 82: 96-104. 10.1016\/j.radonc.2006.11.004.","journal-title":"Radiother Oncol"},{"key":"90_CR24","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.4161\/cbt.5.9.3175","volume":"5","author":"JE Dancey","year":"2006","unstructured":"Dancey JE: Therapeutic targets: MTOR and related pathways. Cancer Biol Ther. 2006, 5: 1065-1073.","journal-title":"Cancer Biol Ther"},{"key":"90_CR25","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.bbrc.2003.09.132","volume":"310","author":"N Gao","year":"2003","unstructured":"Gao N, Zhang Z, Jiang BH, Shi X: Role of PI3K\/AKT\/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun. 2003, 310: 1124-32. 10.1016\/j.bbrc.2003.09.132.","journal-title":"Biochem Biophys Res Commun"},{"key":"90_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1464-410X.2004.04574.x","volume":"93","author":"X Wu","year":"2004","unstructured":"Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, Sweeney C: The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int. 2004, 93: 143-150. 10.1111\/j.1464-410X.2004.04574.x.","journal-title":"BJU Int"},{"key":"90_CR27","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/sj.gt.3302056","volume":"10","author":"M Tanaka","year":"2003","unstructured":"Tanaka M, Grossman HB: In vivo gene therapy of human bladder cancer with PTEN suppress tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther. 2003, 10: 1636-1642. 10.1038\/sj.gt.3302056.","journal-title":"Gene Ther"},{"key":"90_CR28","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1097\/00007890-200205270-00008","volume":"73","author":"FL Luan","year":"2002","unstructured":"Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M: Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation. 2002, 73: 1565-1572. 10.1097\/00007890-200205270-00008.","journal-title":"Transplantation"},{"key":"90_CR29","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1186\/bcr1344","volume":"7","author":"T Kasukabe","year":"2005","unstructured":"Kasukabe T, Okabe-Kado J, Kato N, Sassa T, Honma Y: Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res. 2005, 7: 1097-1110. 10.1186\/bcr1344.","journal-title":"Breast Cancer Res"},{"key":"90_CR30","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","volume":"5","author":"E Buck","year":"2006","unstructured":"Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther. 2006, 5: 2676-2684. 10.1158\/1535-7163.MCT-06-0166.","journal-title":"Mol Cancer Ther"},{"key":"90_CR31","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1158\/1535-7163.MCT-07-0235","volume":"6","author":"JD Mosley","year":"2007","unstructured":"Mosley JD, Poirier JT, Seachrist DD, Landis MD, Keri RA: Rapamycin inhibits multiple stages of c-Neu\/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol Cancer Ther. 2007, 6: 2188-2197. 10.1158\/1535-7163.MCT-07-0235.","journal-title":"Mol Cancer Ther"},{"key":"90_CR32","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1158\/1078-0432.CCR-06-2770","volume":"13","author":"S Mabuchi","year":"2007","unstructured":"Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR: RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007, 13: 4261-4270. 10.1158\/1078-0432.CCR-06-2770.","journal-title":"Clin Cancer Res"},{"key":"90_CR33","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","volume":"67","author":"RJ Dowling","year":"2007","unstructured":"Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007, 67: 10804-10812. 10.1158\/0008-5472.CAN-07-2310.","journal-title":"Cancer Res"},{"key":"90_CR34","first-page":"2129","volume":"54","author":"T Okada","year":"2007","unstructured":"Okada T, Sawada T, Kubota K: Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells. Hepatogastroenterology. 2007, 54: 2129-2133.","journal-title":"Hepatogastroenterology"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-28-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T01:34:11Z","timestamp":1630460051000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-28-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["90"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-28-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"4 November 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"3"}}